The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion supporting Novo’s hemophilia A preventive therapy and also recommended approval of seven other medicines plus 11 label expansions. The CHMP recommendation is a key step toward European authorization, moving products closer to final European Commission decisions. The update underscores continuing throughput in the EU regulatory pathway, with hemophilia representing an area of sustained innovation for prophylaxis and bleed prevention strategies. For companies with products under review, CHMP signals also influence partner discussions, rollout planning, and regional launch timing. Investors and clinicians will watch how the final European Commission decision aligns with the CHMP’s recommended labeling and any conditions that may be attached.